NAT10 and gastric cancer: Inhibition of NAT10 with Remodelin reduces cardiac hypertrophy, fibrosis, and inflammation, making it a promising therapeutic target in heart failure.[49] Similarly, ac4C modification by NAT10 enhances hypoxia tolerance in gastric cancer through glycolysis addiction.